Medicare AdvantageFebruary 16, 2024
Anthem expands specialty pharmacy precertification list
Update: In the February 2024 edition of Provider News, we announced prior authorizations for the following drugs would be effective May 1, 2024. Please be advised that the prior authorization effective date for the drugs listed below will be June 1, 2024.
HCPCS or CPT® codes | Medicare Part B drugs |
C9399 | Adzynma (ADAMTS13, recombinant-krhn) |
J3490, J3590, J9999 | Aphexda (motixafortide) |
C9160 | Daxxify (daxibotulinumtoxinA-lanm) |
J3490 | Focinvez (fosaprepitant) |
J3590 | Omvoh (mirikizumab-mrkz) |
J3490, J3590 | Tofidence (tocilizumab-bavi) |
Effective for dates of service on and after June 1, 2024, the specialty Medicare Part B drug listed in the table below will be included in our precertification review process.
Federal and state law, as well as state contract language and CMS guidelines, including definitions and specific contract provisions/exclusions, take precedence over these precertification rules and must be considered first when determining coverage. Noncompliance with new requirements may result in denied claims.
HCPCS or CPT codes | Medicare Part B drugs |
J3490, J3590 | Avzivi (bevacizumab-tnjn) |
C9399, J3490, J3590 | Loqtorzi (toripalimab-tpzi) |
J3490 | Rivfloza (nedosiran) |
J3490, J3590 | Ryzneuta (efbemalenograstim alfa-vuxw) |
C9399, J3490 | Wainua (eplontersen) |
Notification of specialty pharmacy medical step therapy updates
Effective June 1, 2024, the following Part B medications from the current Clinical Criteria Guidelines will be included in our medical step therapy precertification review process. Step therapy review will apply upon precertification initiation in addition to the current medical necessity review (as is current procedure). Step therapy will not apply for members who are actively receiving medications listed below.
Clinical UM Guidelines are publicly available on the provider website. Visit the Clinical Criteria page to search for specific criteria.
Clinical UM Guidelines | Preferred drug(s) | Nonpreferred drug(s) |
CC-0107 | Avastin Mvasi | Avzivi Alymsys Vegzelma Zirabev |
CC-0002 | Neulasta Neulasta OnPro Udenyca | Ryzneuta Fulphila Fylnetra Nyvepria Rolvedon Stimufend Ziextenzo |
Anthem Blue Cross and Blue Shield is the trade name of Community Insurance Company. Independent licensee(s) of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc.
MULTI-BCBS-CR-051073-24-CPN50794
PUBLICATIONS: March 2024 Provider Newsletter
To view this article online:
Or scan this QR code with your phone